Sirwan K L Darweesh1, Frank J Wolters1, M Arfan Ikram2, Frank de Wolf3, Daniel Bos4, Albert Hofman5. 1. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 2. Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Neurology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 3. Janssen Prevention Center, Leiden, the Netherlands; Faculty of Medicine, School of Public Health, Imperial College London, London, UK. 4. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands; Department of Radiology and Nuclear Medicine, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. 5. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA, USA; Department of Epidemiology, Erasmus MC University Medical Center Rotterdam, Rotterdam, the Netherlands. Electronic address: ahofman@hsph.harvard.edu.
Abstract
INTRODUCTION: Inflammatory markers are often elevated in patients with dementia, including Alzheimer's disease (AD). However, it remains unclear whether inflammatory markers are associated with the risk of developing dementia. METHODS: We searched PubMed, Embase, and Cochrane library for prospective population-based studies reporting associations between inflammatory markers and all-cause dementia or AD. We used random effects meta-analyses to obtain pooled hazard ratios (HRs) and 95% confidence intervals of inflammatory markers (highest vs. lowest quantile) for all-cause dementia and AD. RESULTS: Fifteen articles from 13 studies in six countries reported data that could be meta-analyzed. C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD. DISCUSSION: Several inflammatory markers are associated with an increased risk of all-cause dementia; however, these markers are not specific for AD. Whether inflammatory markers closely involved in AD pathology are associated with the risk of AD remains to be elucidated.
INTRODUCTION: Inflammatory markers are often elevated in patients with dementia, including Alzheimer's disease (AD). However, it remains unclear whether inflammatory markers are associated with the risk of developing dementia. METHODS: We searched PubMed, Embase, and Cochrane library for prospective population-based studies reporting associations between inflammatory markers and all-cause dementia or AD. We used random effects meta-analyses to obtain pooled hazard ratios (HRs) and 95% confidence intervals of inflammatory markers (highest vs. lowest quantile) for all-cause dementia and AD. RESULTS: Fifteen articles from 13 studies in six countries reported data that could be meta-analyzed. C-reactive protein (HR = 1.37 [1.05; 1.78]), interleukin-6 (HR = 1.40 [1.13; 1.73]), α1-antichymotrypsin (HR = 1.54 [1.14; 2.80]), lipoprotein-associated phospholipase A2 activity (HR = 1.40 [1.03; 1.90]), and fibrinogen were each associated with all-cause dementia, but neither was significantly associated with AD. DISCUSSION: Several inflammatory markers are associated with an increased risk of all-cause dementia; however, these markers are not specific for AD. Whether inflammatory markers closely involved in AD pathology are associated with the risk of AD remains to be elucidated.
Authors: May A Beydoun; Jordan Weiss; Hardeep K Obhi; Hind A Beydoun; Gregory A Dore; Hailun Liang; Michele K Evans; Alan B Zonderman Journal: Brain Behav Immun Date: 2019-04-11 Impact factor: 7.217
Authors: E Lydia Wu-Chung; Stephanie L Leal; Bryan T Denny; Samantha L Cheng; Christopher P Fagundes Journal: Neurosci Biobehav Rev Date: 2021-12-29 Impact factor: 8.989
Authors: Shannon D Donofry; Chelsea M Stillman; Jamie L Hanson; Margaret Sheridan; Shufang Sun; Eric B Loucks; Kirk I Erickson Journal: Neurosci Biobehav Rev Date: 2021-10-05 Impact factor: 8.989
Authors: Lana Fani; Marios K Georgakis; M Arfan Ikram; M Kamran Ikram; Rainer Malik; Martin Dichgans Journal: Transl Psychiatry Date: 2021-05-17 Impact factor: 6.222